Hillstar Bio develops next-generation precision immunology therapies that selectively deplete pathogenic immune cells while preserving healthy cells. Its lead program targets TRBV9+ T cells and is being advanced toward a clinical proof-of-concept study in axial spondyloarthritis and other HLA-B27-associated conditions. The company plans to initiate clinical trials for the TRBV9 program in 2026. Hillstar leverages tailored discovery techniques, validated technologies, and disease-specific biomarkers to identify patient populations and mitigate development risk. The company is backed by an investor syndicate and says it is fully funded through early clinical studies following the recent financing. Hillstar highlights a leadership team with deep expertise in antibody engineering, immunology, and clinical development.

Total raised

$67M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2025